

## VI. Period of Agreement

The agreement becomes effective upon signature of both parties and will continue without expiration. It may be modified by mutual consent or terminated by either party upon 120 days written notice.

APPROVED AND ACCEPTED FOR  
THE NATIONAL LIBRARY OF  
MEDICINE

By




Betsy Humphreys  
Deputy Director  
National Library of Medicine

Date

6/23/2005

APPROVED AND ACCEPTED FOR  
THE CENTER FOR DRUG EVALUATION  
AND RESEARCH

By



Janet Woodcock, MD (Acting)  
Deputy Commissioner for Operations  
Office of the Commissioner

Date

7/04/05

[FR Doc. 05-19340 Filed 9-27-05; 8:45 am]  
BILLING CODE 4160-01-C

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), notice is hereby given of the following meeting:

*Name:* Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children (ACHDGDNC).

*Dates and Times:* October 20, 2005, 9 a.m. to 5 p.m.; October 21, 2005, 9 a.m. to 3 p.m.

*Place:* Ronald Reagan Building and International Trade Center, 1300 Pennsylvania Avenue, NW., Washington, DC 20004.

*Status:* The meeting will be open to the public with attendance limited to space availability.

*Purpose:* The Advisory Committee provides advice and recommendations concerning the grants and projects authorized under the Heritable Disorders Program and technical information to develop policies and priorities for this program. The Heritable Disorders Program was established to enhance the ability of State and local health agencies to provide for newborn and child screening, counseling and health care services for newborns and children having or at risk for heritable disorders. The Committee was established specifically to advise and guide the Secretary regarding the most appropriate application of universal newborn screening tests, technologies, policies, guidelines and programs for effectively reducing morbidity and mortality in

newborns and children having or at risk for heritable disorders.

*Agenda:* The first day will be devoted to presentations on and a discussion of the decision-making methodology of the Committee and an update of the current status of State specific issues. The second day will include meetings and reports from the Committee's subcommittees on laboratory standards and procedures, follow-up and treatment and education and training.

Proposed agenda items are subject to change.

*Public Comments:* Time will be provided each day for public comment. Individuals who wish to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the ACHDGDNC Executive Secretary, Michele A. Lloyd-Puryear, M.D., Ph.D. (contact information provided below).

*Contact Person:* Anyone interested in obtaining a roster of members or other relevant information should write or contact Michele A. Lloyd-Puryear, M.D., Ph.D., Maternal and Child Health Bureau, Health Resources and Services Administration, Room 18A-19, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-1080. Information on the Advisory Committee is available at <http://mchb.hrsa.gov/programs/genetics/committee>.

Dated: September 20, 2005.

**Tina M. Cheatham,**

Director, Division of Policy Review and Coordination.

[FR Doc. 05-19295 Filed 9-27-05; 8:45 am]

BILLING CODE 4165-15-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Director's Council of Public Representatives.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Director's Council of Public Representatives.

*Date:* October 25, 2005.

*Time:* 8:30 a.m. to 3 p.m.

*Agenda:* Among the topics proposed for discussion are: (1) NIH Director's update; (2) COPR workgroup reports; (3) public perspective on the NIH Roadmap; (4) updates on the NIH Re-authorization and the Office of Portfolio Analysis and Strategic Initiatives; (5) NIH response to COPR's Public Trust Report; and (6) discussion and public comment.

*Place:* National Institutes of Health, Building 31, Conference Room 6, 9000 Rockville Pike, Bethesda, MD 20892.

*Contact Person:* Jennifer E. Gorman Vetter, NIH Public Liaison/COPR Coordinator, Office of Communications and Public Liaison, Office of the Director, National Institutes of Health, 9000 Rockville Pike, Building 1, Room 344, Bethesda, MD 20892. (301) 435-4448. [gormanj@od.nih.gov](mailto:gormanj@od.nih.gov).

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this

notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D. and sign-in at the security desk upon entering the building.

Information is also available on the Institute's/Center's home page: [www.copr.nih.gov](http://www.copr.nih.gov), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: September 21, 2005.

**Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-19386 Filed 9-27-05; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Notice of Meeting: Secretary's Advisory Committee on Genetics, Health, and Society

Pursuant to Public Law 92-463, notice is hereby given of the eighth meeting of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), U.S. Public Health Service. The meeting will be held from 8:30 a.m. to 6 p.m. on October 19, 2005 and 8:30 a.m. to 5 p.m. on October 20, 2005 at the Bethesda North Marriott Hotel, 5701 Marinelli Road, North Bethesda, Maryland. The meeting will be open to the public with attendance

limited to space available. The meeting will be webcast.

The first half of the meeting will be devoted to the issue of large population studies of genetic variation, the environment and common disease. The Committee is working to identify salient scientific, ethical, and policy issues and questions associated with such studies and processes that could be employed to address them. On October 19, the Committee will gather input from several leaders in science and bioethics about the policy issues and how to address them, including mechanisms for engaging the general public. October 20th will be devoted to the further exploration of current issues in pharmacogenomics. The Committee is developing a report to the Secretary on this topic, and at this meeting they will explore the financial and economic considerations involved in integrating pharmacogenomics into clinical practice as well as delve more deeply into certain ethical, legal and social issues raised by pharmacogenomics. Time will be provided each day for public comments, and the public is encouraged to provide its perspectives to the committee on these topics or any others related to the development and use of genetic technologies.

Under authority of 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established SACGHS to serve as a public forum for deliberations on the broad range of human health and societal issues raised by the development and use of genetic technologies and, as warranted, to provide advice on these issues. The draft meeting agenda and other information about SACGHS, including information about access to the webcast, will be available at the following Web site: <http://www4.od.nih.gov/oba/sacghs.htm>.

The Committee would welcome hearing from anyone wishing to provide public comment on any issue related to genetics, health and society. Individuals who would like to provide public comment or who plan to attend the meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the SACGHS Executive Secretary, Ms. Sarah Carr, by telephone at (301) 496-9838 or e-mail at [sc112c@nih.gov](mailto:sc112c@nih.gov). The SACGHS office is located at 6705 Rockledge Drive, Suite 750, Bethesda, MD 20892.

Dated: September 21, 2005.

**Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-19387 Filed 9-27-05; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Notice of Meeting; Interagency Autism Coordinating Committee

The National Institutes of Health (NIH) hereby announces a meeting of the Interagency Autism Coordinating Committee to be held on November 18, 2005, on the NIH campus in Bethesda, Maryland.

The Children's Health Act of 2000 (Pub. L. 106-310), Title I, Section 104, mandated the establishment of an Interagency Autism Coordinating Committee (IACC) to coordinate autism research and other efforts within the Department of Health and Human Services (HHS). In April 2001, the HHS Secretary delegated the authority to establish the IACC to the NIH. The National Institute of Mental Health (NIMH) at the NIH has been designated the lead for this activity.

The IACC meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person listed below in advance of the meeting.

*Name of Committee:* Interagency Autism Coordinating Committee.

*Date:* November 18, 2005.

*Time:* 9 a.m.-4:30 p.m.

*Agenda:* Discussion of autism activities across Federal agencies.

*Place:* National Institutes of Health, 31 Center Drive, Building 31, Conference Room 10 (6th floor), Bethesda, Maryland 20892.

*Contact Person:* Ann Wagner, Ph.D., Division of Services and Intervention Research, National Institute of Mental Health, NIH, 6001 Executive Boulevard, Room 6184, MSC 9617, Bethesda, Maryland 20892, E-mail: [awagner@mail.nih.gov](mailto:awagner@mail.nih.gov), Phone: (301) 443-5944.

Any member of the public interested in presenting oral comments to the Committee may notify the contact person listed on this notice at least 5 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Presentations may be limited to 5 minutes; both printed and electronic copies are requested for the record. In addition, any interested person may file written comments